A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 27; p. vi350
Main Authors Argiris, A., Gillison, M., Ferris, R.L., Harrington, K., Sanchez, T.K., Baudelet, C., Geese, W.J., Shaw, J., Haddad, R.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.10.2016
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdw376.68